For everyone, everywhere

OUR PERSPECTIVE

Shortcomings of existing therapies

Current standard of care treatments are ineffective for millions worldwide.

Significant burden

~1bn

Affected People

Global population with mental health disorders

>50%

Of US population impacted

Expected that more than half of US population will have a mental health disorder at some point in their lifetime

~$16tn

Global economic impact

Estimated global economic costs of mental health disorders by 2030

~4x

Recent impact of COVID-19

Percentage of US adults experiencing symptoms of depression and anxiety rose from 11% in 2019 to 42% end of 2020

Urgent need for innovation

~33%

Respond inadequately

A third of patients with depression respond inadequately or relapse with current treatments within certain indications

Up to 12 wks

Slow onset of treatment effect

Frontline treatments for depression and anxiety have slow onset (4-12w)

~75%

Relapse rate

Most of the patients treated for opioid use disorder (OUD) relapse

7

Psychiatry approvals since 2015

Only 7 new drugs approved by the FDA for psychiatry disorders since 2015 – less than 10% relative to oncology (N=83)

Our unique approach

microscope icon

Compounds with prior evidence in humans

To minimize development risk, we focus on compounds that have previously been used in humans and have established safety profiles.

https://www.atai.life/wp-content/uploads/2020/11/home-1b.png
data icon

Enabling platform technologies

Leveraging proprietary technology to accelerate drug discovery, reposition existing molecules with big data approaches, and improve patient outcomes with digital therapeutics.
https://www.atai.life/wp-content/uploads/2020/11/home-2b.png
platform-model icon

Decentralized drug development

In addition to funding, our evolving companies have access to our deep domain expertise and operational backbone.

https://www.atai.life/wp-content/uploads/2020/11/home-3b.png

Learn more about our approach

OUR MODEL
WHERE WE’RE HEADED

Our technologies drive efficient drug discovery and improved treatment outcomes.

Our unique model combines funding with operational expertise to develop innovative and impactful CNS therapeutics. 

OUR MODEL

News & Insights

JOIN THE ATAI #INSIGHTNETWORK

Sign up to receive the latest news on atai.

Email
submit